Listed

Thermo Fisher Scientific Inc.

TMONYSECIK 97745TechnologyFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$11.99bnRevenue, Q2 FY2026, three months to 2026-06-27$11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figureThree months to Jun 27, 2026, from the 10-Q filed Jul 31, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 27, 2026, against the same quarter a year earlier.

  • Revenue$11.99bnRevenue, Q2 FY2026, three months to 2026-06-27$11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure+10.5% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin17.4%Operating margin, Q2 FY2026, three months to 2026-06-27. operating income / revenueOperating income: $2.09bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure+0.5 pts on a year earlier
  • Net margin14.5%Net margin, Q2 FY2026, three months to 2026-06-27. net income / revenueNet income: $1.74bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure−0.4 pts on a year earlier
  • Diluted EPS$4.68Diluted EPS, Q2 FY2026, three months to 2026-06-27$4.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure+9.3% on a year earlier
  • Free cash flow$1.68bnFree cash flow, Q2 FY2026, three months to 2026-06-27. operating cash flow − capital expenditureOperating cash flow: $2.13bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Capital expenditure: $450.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Report this figure+51.6% on a year earlier

Last eight quarters

Full statements
Revenue$11.99bnOperating margin 17.4%
Diluted EPS$4.68, Q2 FY2026
Free cash flow$1.68bn, Q2 FY2026
Thermo Fisher Scientific Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-28Q4 FY20242024-12-31Q1 FY20252025-03-29Q2 FY20252025-06-28Q3 FY20252025-09-27Q4 FY20252025-12-31Q1 FY20262026-03-28Q2 FY20262026-06-27Shape over the periods
Revenue$bn10.6Revenue, Q3 FY2024, three months to 2024-09-28$10.60bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure11.4Revenue, Q4 FY2024, three months to 2024-12-31$11.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure10.4Revenue, Q1 FY2025, three months to 2025-03-29$10.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure10.9Revenue, Q2 FY2025, three months to 2025-06-28$10.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure11.1Revenue, Q3 FY2025, three months to 2025-09-27$11.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure12.2Revenue, Q4 FY2025, three months to 2025-12-31$12.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure11.0Revenue, Q1 FY2026, three months to 2026-03-28$11.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure12.0Revenue, Q2 FY2026, three months to 2026-06-27$11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%17.3%Operating margin, Q3 FY2024, three months to 2024-09-28. operating income / revenueOperating income: $1.84bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Revenue: $10.60bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure17.7%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $2.02bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $11.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure16.6%Operating margin, Q1 FY2025, three months to 2025-03-29. operating income / revenueOperating income: $1.72bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Revenue: $10.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure16.9%Operating margin, Q2 FY2025, three months to 2025-06-28. operating income / revenueOperating income: $1.83bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $10.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure17.5%Operating margin, Q3 FY2025, three months to 2025-09-27. operating income / revenueOperating income: $1.94bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Revenue: $11.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure18.5%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $2.25bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $12.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure16.9%Operating margin, Q1 FY2026, three months to 2026-03-28. operating income / revenueOperating income: $1.86bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Revenue: $11.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure17.4%Operating margin, Q2 FY2026, three months to 2026-06-27. operating income / revenueOperating income: $2.09bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure
Net margin%15.4%Net margin, Q3 FY2024, three months to 2024-09-28. net income / revenueNet income: $1.63bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Revenue: $10.60bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure16.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $1.83bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $11.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure14.5%Net margin, Q1 FY2025, three months to 2025-03-29. net income / revenueNet income: $1.51bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Revenue: $10.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure14.9%Net margin, Q2 FY2025, three months to 2025-06-28. net income / revenueNet income: $1.62bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $10.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure14.5%Net margin, Q3 FY2025, three months to 2025-09-27. net income / revenueNet income: $1.62bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Revenue: $11.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figure16.1%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $1.96bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Revenue: $12.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure15.0%Net margin, Q1 FY2026, three months to 2026-03-28. net income / revenueNet income: $1.65bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Revenue: $11.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure14.5%Net margin, Q2 FY2026, three months to 2026-06-27. net income / revenueNet income: $1.74bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Revenue: $11.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure
Diluted EPS$ per share4.25Diluted EPS, Q3 FY2024, three months to 2024-09-28$4.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figurenot reported (Diluted EPS not reported)3.98Diluted EPS, Q1 FY2025, three months to 2025-03-29$3.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure4.28Diluted EPS, Q2 FY2025, three months to 2025-06-28$4.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure4.27Diluted EPS, Q3 FY2025, three months to 2025-09-27$4.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-31, accession 0000097745-25-000159.Report this figurenot reported (Diluted EPS not reported)4.43Diluted EPS, Q1 FY2026, three months to 2026-03-28$4.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure4.68Diluted EPS, Q2 FY2026, three months to 2026-06-27$4.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000097745-26-000144.Report this figure
Free cash flow$bn1.9Free cash flow, Q3 FY2024, three months to 2024-09-28. operating cash flow − capital expenditureOperating cash flow: $2.17bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-31, accession 0000097745-25-000159. Derived: 9-month figure less the 6-month figure.Capital expenditure: $272.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-31, accession 0000097745-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure2.8Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $3.29bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Capital expenditure: $480.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.4Free cash flow, Q1 FY2025, three months to 2025-03-29. operating cash flow − capital expenditureOperating cash flow: $723.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Capital expenditure: $362.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure1.1Free cash flow, Q2 FY2025, three months to 2025-06-28. operating cash flow − capital expenditureOperating cash flow: $1.40bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Capital expenditure: $294.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Report this figure1.8Free cash flow, Q3 FY2025, three months to 2025-09-27. operating cash flow − capital expenditureOperating cash flow: $2.24bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-31, accession 0000097745-25-000159. Derived: 9-month figure less the 6-month figure.Capital expenditure: $404.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-31, accession 0000097745-25-000159. Derived: 9-month figure less the 6-month figure.Report this figure3.0Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $3.46bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Capital expenditure: $465.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000097745-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.8Free cash flow, Q1 FY2026, three months to 2026-03-28. operating cash flow − capital expenditureOperating cash flow: $1.19bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Capital expenditure: $376.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0000097745-26-000092.Report this figure1.7Free cash flow, Q2 FY2026, three months to 2026-06-27. operating cash flow − capital expenditureOperating cash flow: $2.13bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Capital expenditure: $450.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000097745-26-000144. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$44.56bnOperating margin 17.4%
Diluted EPS$17.74, FY2025
Free cash flow$6.29bn, FY2025
Thermo Fisher Scientific Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn39.2Revenue, FY2021, twelve months to 2021-12-31$39.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000097745-24-000007.Report this figure44.9Revenue, FY2022, twelve months to 2022-12-31$44.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000097745-25-000010.Report this figure42.9Revenue, FY2023, twelve months to 2023-12-31$42.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure42.9Revenue, FY2024, twelve months to 2024-12-31$42.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure44.6Revenue, FY2025, twelve months to 2025-12-31$44.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%25.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $10.03bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0000097745-24-000007.Revenue: $39.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000097745-24-000007.Report this figure18.7%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $8.39bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-20, accession 0000097745-25-000010.Revenue: $44.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000097745-25-000010.Report this figure16.0%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $6.86bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $42.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure17.1%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $7.34bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $42.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure17.4%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $7.75bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $44.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure
Net margin%19.7%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $7.73bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2024-02-22, accession 0000097745-24-000007.Revenue: $39.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000097745-24-000007.Report this figure15.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $6.96bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2025-02-20, accession 0000097745-25-000010.Revenue: $44.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000097745-25-000010.Report this figure14.0%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $6.00bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $42.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure14.8%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $6.33bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $42.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure15.0%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $6.70bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000097745-26-000018.Revenue: $44.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure
Diluted EPS$ per share19.46Diluted EPS, FY2021, twelve months to 2021-12-31$19.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0000097745-24-000007.Report this figure17.63Diluted EPS, FY2022, twelve months to 2022-12-31$17.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-20, accession 0000097745-25-000010.Report this figure15.45Diluted EPS, FY2023, twelve months to 2023-12-31$15.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure16.53Diluted EPS, FY2024, twelve months to 2024-12-31$16.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure17.74Diluted EPS, FY2025, twelve months to 2025-12-31$17.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure
Free cash flow$bn6.8Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $9.31bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0000097745-24-000007.Capital expenditure: $2.52bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0000097745-24-000007.Report this figure6.9Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $9.15bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-20, accession 0000097745-25-000010.Capital expenditure: $2.24bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-20, accession 0000097745-25-000010.Report this figure6.9Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $8.41bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000097745-26-000018.Capital expenditure: $1.48bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure7.3Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $8.67bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000097745-26-000018.Capital expenditure: $1.40bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure6.3Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $7.82bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000097745-26-000018.Capital expenditure: $1.52bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000097745-26-000018.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Thermo Fisher Scientific Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$15.50bn30,919,632Added+492,440
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$12.17bn24,276,316Reduced−4,500
STATE STREET CORP2026-06-30$8.44bn16,825,879Added+94,211
FMR LLC2026-06-30$7.06bn14,084,488Added+3,308,052
MORGAN STANLEY2026-06-30$5.40bn10,763,066Reduced−100,462
JPMORGAN CHASE & CO2026-06-30$4.31bn8,503,527Added+1,708,045
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$4.18bn8,382,401Reduced−25,490
FRANKLIN RESOURCES INC2026-06-30$3.65bn7,271,514Added+458,483
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$3.12bn6,226,169Added+62,799
Capital World Investors2026-06-30$3.11bn6,195,370Reduced−450,946

Recent filings

All 2,304 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Thermo Fisher Scientific Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2110:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000097745-26-000173
2026-07-3114:51 ET10-QQuarterly reportPeriod 2026-06-270000097745-26-000144
2026-07-2310:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000097745-26-000138
2026-05-2611:31 ET8-K5.07 Shareholder vote results0000097745-26-000117
2026-05-0115:00 ET10-QQuarterly reportPeriod 2026-03-280000097745-26-000092
2026-04-2310:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000097745-26-000086
2026-04-0712:14 ETDEF 14AProxy statementPeriod 2026-05-200001193125-26-144585
2026-03-2412:02 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000097745-26-000066
2026-02-2617:11 ET10-KAnnual reportPeriod 2025-12-310000097745-26-000018
2026-02-1221:19 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001140361-26-005014

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
97745
Tickers
TMO
Exchange
NYSE
SIC code
3829 Measuring & Controlling Devices, NEC
Sector
Technology
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
THERMO ELECTRON CORP (to 2006-11-03)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. Listed shows no prices and gives no investment advice.